AbbVie ABBV Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Net revenues by Product | |||||
| All other | $3.13B+3.3% | $3.03B-0.1% | $3.04B-26.6% | $4.14B-17.6% | |
| Botox Cosmetic | $2.6B-4.3% | $2.72B+1.4% | $2.68B+2.6% | $2.62B+17.2% | |
| Botox Therapeutic | $3.77B+14.8% | $3.28B+9.8% | $2.99B+10.0% | $2.72B+10.9% | |
| Elahere | $690M+44.1% | $479M— | $0— | $0— | |
| Epkinly | $271M+85.6% | $146M+371% | $31M— | —— | |
| Humira | $4.54B-49.5% | $8.99B-37.6% | $14.4B-32.2% | $21.24B+2.6% | |
| Imbruvica | $2.87B-14.3% | $3.35B-6.9% | $3.6B-21.3% | $4.57B-15.5% | |
| Juvederm Collection | $993M-15.6% | $1.18B-14.6% | $1.38B-3.5% | $1.43B-7.0% | |
| Linzess | $907M-4.9% | $954M-13.9% | $1.11B+7.1% | $1.04B-0.3% | |
| Mavyret | $1.32B+0.5% | $1.31B-8.3% | $1.43B-7.2% | $1.54B-9.9% | |
| Other Aesthetics | $1.27B-1.1% | $1.28B+3.6% | $1.23B-4.3% | $1.29B-12.0% | |
| Other Neuroscience | $303M+26.8% | $239M-12.5% | $273M-42.5% | $475M-30.7% | |
| Qulipta | $1.04B+57.4% | $658M+61.3% | $408M+158% | $158M— | |
| Rinvoq | $8.3B+39.1% | $5.97B+50.4% | $3.97B+57.4% | $2.52B+52.8% | |
| Skyrizi | $17.56B+49.9% | $11.72B+50.9% | $7.76B+50.3% | $5.17B+75.7% | |
| Ubrelvy | $1.27B+26.3% | $1.01B+23.4% | $815M+19.9% | $680M+23.2% | |
| Venclexta | $2.79B+8.1% | $2.58B+12.9% | $2.29B+13.9% | $2.01B+10.4% | |
| Vraylar | $3.62B+10.8% | $3.27B+18.4% | $2.76B+35.4% | $2.04B+17.9% | |
| Vyalev | $482M+387% | $99M+3,200% | $3M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does AbbVie break its business down?
- AbbVie (ABBV) reports net revenues by product across 19 parts — All other, Botox Cosmetic, Botox Therapeutic, Elahere and Epkinly. Each is extracted from the segment footnotes and tracked over time.
- Where does AbbVie's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in AbbVie's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
